Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free RCUS Stock Alerts

Arcus Biosciences (RCUS) Financials

Arcus Biosciences logo
$24.99 -0.01 (-0.06%)
Closing price 03:59 PM Eastern
Extended Trading
$24.57 -0.42 (-1.66%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Arcus Biosciences

Annual Income Statements for Arcus Biosciences

This table shows Arcus Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -18 -53 -50 -85 -123 53 -267 -307 -283 -353
Consolidated Net Income / (Loss)		 -18 -53 -50 -85 -123 53 -267 -307 -283 -353
Net Income / (Loss) Continuing Operations		 -18 -53 -50 -85 -123 53 -267 -307 -283 -353
Total Pre-Tax Income 		-18 -53 -50 -85 -123 55 -266 -301 -282 -353
Total Operating Income		 -18 -53 -55 -89 -124 54 -280 -340 -330 -386
Total Gross Profit		 0.00 1.41 8.35 15 78 383 112 117 258 247
Total Revenue		 0.00 1.41 8.35 15 78 383 112 117 258 247
Operating Revenue		 0.00 1.41 8.35 15 78 383 112 117 258 247
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 18 55 63 104 202 329 392 457 588 633
Selling, General & Admin Expense		 3.94 7.64 14 25 43 72 104 117 120 110
Research & Development Expense		 14 47 50 78 159 257 288 340 448 523
Total Other Income / (Expense), net		 0.21 0.36 5.27 4.00 1.00 1.00 14 39 48 33
Interest Expense		 - - - - 0.00 0.00 2.00 2.00 4.00 8.00
Other Income / (Expense), net		 - 0.78 4.92 5.20 1.00 1.00 16 41 52 41
Income Tax Expense		 - - - 0.00 0.00 2.00 1.00 6.00 1.00 0.00
Basic Earnings per Share		 ($20.80) - - - - - ($3.71) ($4.15) ($3.14) ($3.29)
Weighted Average Basic Shares Outstanding		 863.98K 1.83M 34.62M 43.83M 54.80M 69.30M 72M 74M 90.10M 107.40M
Diluted Earnings per Share		 ($20.80) - - - - - ($3.71) ($4.15) ($3.14) ($3.29)
Weighted Average Diluted Shares Outstanding		 863.98K 1.83M 34.62M 43.83M 54.80M 74M 72M 74M 90.10M 107.40M
Weighted Average Basic & Diluted Shares Outstanding		 863.98K 1.83M 34.62M 43.83M 54.79M 71.06M 73.01M 90.86M 105.84M 125.35M

Quarterly Income Statements for Arcus Biosciences

This table shows Arcus Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -71 -81 -4.00 -93 -92 -94 -112 0.00 -135 -106 -128
Consolidated Net Income / (Loss)		 -71 -81 -4.00 -93 -92 -94 -112 0.00 -135 -106 -128
Net Income / (Loss) Continuing Operations		 -71 -81 -4.00 -93 -92 -94 -112 0.00 -135 -106 -128
Total Pre-Tax Income 		-69 -80 -4.00 -93 -92 -93 -112 0.00 -135 -106 -128
Total Operating Income		 -80 -91 -16 -106 -105 -103 -122 -8.00 -142 -114 -134
Total Gross Profit		 32 31 145 39 48 26 28 160 26 33 17
Total Revenue		 32 31 145 39 48 26 28 160 26 33 17
Operating Revenue		 32 31 145 39 48 26 28 160 26 33 17
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 112 122 161 145 153 129 150 168 168 147 151
Selling, General & Admin Expense		 30 29 32 30 30 28 28 29 27 26 29
Research & Development Expense		 82 93 109 115 123 101 122 139 141 121 122
Total Other Income / (Expense), net		 11 11 12 13 13 10 10 8.00 7.00 8.00 6.00
Interest Expense		 1.00 - 1.00 0.00 1.00 2.00 1.00 2.00 3.00 2.00 3.00
Other Income / (Expense), net		 12 11 - 13 14 - 11 10 10 10 9.00
Income Tax Expense		 2.00 1.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.94) ($1.08) ($0.05) ($1.02) ($1.00) ($1.07) ($1.14) $0.00 ($1.27) ($0.88) ($1.02)
Weighted Average Basic Shares Outstanding		 74.60M 74M 86.20M 91.10M 91.40M 90.10M 98.40M 106.10M 106.50M 107.40M 125.40M
Diluted Earnings per Share		 ($0.94) ($1.08) ($0.05) ($1.02) ($1.00) ($1.07) ($1.14) $0.00 ($1.27) ($0.88) ($1.02)
Weighted Average Diluted Shares Outstanding		 74.60M 74M 86.20M 91.10M 91.40M 90.10M 98.40M 106.50M 106.50M 107.40M 125.40M
Weighted Average Basic & Diluted Shares Outstanding		 74.86M 90.86M 90.95M 91.43M 91.51M 105.84M 105.89M 106.43M 107.97M 125.35M 125.77M

Annual Cash Flow Statements for Arcus Biosciences

This table details how cash moves in and out of Arcus Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 18 33 -27 -13 116 -23 58 -79 23 72
Net Cash From Operating Activities		 -13 -25 -43 -73 111 -256 438 -306 -170 -482
Net Cash From Continuing Operating Activities		 -13 -25 -43 -73 111 -256 438 -306 -170 -482
Net Income / (Loss) Continuing Operations		 -18 -53 -50 -85 -123 53 -267 -307 -283 -353
Consolidated Net Income / (Loss)		 -18 -53 -50 -85 -123 53 -267 -307 -283 -353
Depreciation Expense		 1.31 2.61 3.66 3.58 3.00 4.00 6.00 8.00 10 10
Amortization Expense		 0.00 0.00 -1.75 -2.64 0.00 5.00 0.00 -19 -25 -13
Non-Cash Adjustments To Reconcile Net Income		 0.09 0.81 5.32 12 22 41 777 96 131 76
Changes in Operating Assets and Liabilities, net		 3.62 25 -0.29 -1.50 209 -359 -78 -84 -3.00 -202
Net Cash From Investing Activities		 -39 -49 -113 59 -434 -4.00 -413 194 -84 66
Net Cash From Continuing Investing Activities		 -39 -49 -113 59 -434 -4.00 -413 194 -84 66
Purchase of Property, Plant & Equipment		 -4.10 -5.51 -3.74 -1.93 -3.00 -26 -6.00 -24 -6.00 -2.00
Purchase of Investments		 -34 -97 -262 -248 -740 -719 -1,241 -788 -1,043 -1,076
Sale and/or Maturity of Investments		 0.00 53 152 309 309 741 837 1,006 965 1,144
Net Cash From Financing Activities		 70 107 129 1.12 439 237 33 33 277 488
Net Cash From Continuing Financing Activities		 70 107 129 1.12 439 237 33 33 277 488
Issuance of Debt		 - - - - - - 0.00 0.00 47 49
Issuance of Common Equity		 0.28 0.89 129 1.22 439 232 23 33 237 439
Other Financing Activities, net		 0.00 -0.37 - - 0.00 5.00 10 0.00 -7.00 0.00
Cash Interest Paid		 - - - - - - 0.00 0.00 1.00 7.00
Cash Income Taxes Paid		 - - - - 0.00 0.00 3.00 5.00 0.00 0.00

Quarterly Cash Flow Statements for Arcus Biosciences

This table details how cash moves in and out of Arcus Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -46 -57 58 -29 45 -51 42 56 -10 -16 -21
Net Cash From Operating Activities		 -63 -88 -2.00 -94 26 -100 -132 -133 -97 -120 -138
Net Cash From Continuing Operating Activities		 -63 -88 -2.00 -94 26 -100 -132 -133 -97 -120 -138
Net Income / (Loss) Continuing Operations		 -71 -81 -4.00 -93 -92 -94 -112 - -135 -106 -128
Consolidated Net Income / (Loss)		 -71 -81 -4.00 -93 -92 -94 -112 - -135 -106 -128
Depreciation Expense		 1.00 3.00 3.00 2.00 2.00 3.00 3.00 2.00 2.00 3.00 2.00
Amortization Expense		 1.00 -12 -6.00 -7.00 -6.00 -6.00 -4.00 -3.00 -3.00 -3.00 -3.00
Non-Cash Adjustments To Reconcile Net Income		 10 41 55 29 32 15 23 16 20 17 29
Changes in Operating Assets and Liabilities, net		 -4.00 -39 -50 -25 90 -18 -42 -148 19 -31 -38
Net Cash From Investing Activities		 11 28 -169 63 -29 51 32 137 79 -182 114
Net Cash From Continuing Investing Activities		 11 28 -169 63 -29 51 32 137 79 -182 114
Purchase of Property, Plant & Equipment		 -10 -6.00 -4.00 - -1.00 -1.00 -1.00 - - -1.00 0.00
Purchase of Investments		 -280 -115 -387 -206 -278 -172 -353 -161 -165 -397 -150
Sale and/or Maturity of Investments		 301 149 222 269 250 224 386 298 244 216 264
Net Cash From Financing Activities		 6.00 3.00 229 2.00 48 -2.00 142 52 8.00 286 3.00
Net Cash From Continuing Financing Activities		 6.00 3.00 229 2.00 48 -2.00 142 52 8.00 286 3.00
Issuance of Common Equity		 6.00 3.00 229 3.00 2.00 3.00 142 3.00 8.00 286 3.00

Annual Balance Sheets for Arcus Biosciences

This table presents Arcus Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 190 275 203 772 1,592 1,345 1,095 1,150 1,139
Total Current Assets		 177 259 193 736 1,262 1,067 831 1,016 1,007
Cash & Equivalents		 98 71 58 173 148 206 127 150 222
Short-Term Investments		 77 185 130 555 351 803 632 828 759
Prepaid Expenses		 1.14 2.32 4.05 5.47 18 19 34 18 15
Other Current Assets		 - 0.00 0.13 1.05 745 39 38 20 11
Plant, Property, & Equipment, net		 11 11 9.33 11 32 35 51 47 40
Total Noncurrent Assets		 2.39 4.87 1.08 26 298 243 213 87 92
Long-Term Investments		 0.68 4.38 0.00 6.44 182 129 107 14 29
Other Noncurrent Operating Assets		 1.71 0.49 1.08 19 116 114 106 73 63
Total Liabilities & Shareholders' Equity		 190 275 203 772 1,592 1,345 1,095 1,150 1,139
Total Liabilities		 37 40 39 270 750 688 633 665 508
Total Current Liabilities		 13 17 23 122 166 193 184 226 231
Accounts Payable		 3.82 3.10 4.70 16 10 20 17 18 42
Current Deferred Revenue		 5.00 6.25 7.00 75 102 97 91 85 35
Other Current Liabilities		 0.77 1.56 1.48 3.57 54 76 76 123 154
Total Noncurrent Liabilities		 24 23 17 148 584 495 449 439 277
Long-Term Debt		 - - - - - - 0.00 48 99
Noncurrent Deferred Revenue		 23 21 16 133 462 355 307 234 43
Other Noncurrent Operating Liabilities		 0.57 1.79 0.81 16 122 140 142 157 135
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -72 235 164 502 842 657 462 485 631
Total Preferred & Common Equity		 -72 235 164 502 842 657 462 485 631
Total Common Equity		 -72 235 164 502 842 657 462 485 631
Common Stock		 0.95 358 369 830 1,118 1,206 1,311 1,617 2,116
Retained Earnings		 -73 -123 -205 -328 -275 -542 -849 -1,132 -1,485
Accumulated Other Comprehensive Income / (Loss)		 -0.04 -0.11 0.06 0.04 -1.00 -7.00 - - 0.00

Quarterly Balance Sheets for Arcus Biosciences

This table presents Arcus Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 1,394 1,254 1,220 1,191 1,293 1,186 1,252 1,156 1,075 974 997
Total Current Assets		 1,101 1,015 986 882 1,064 1,022 1,127 1,031 946 857 844
Cash & Equivalents		 218 238 230 184 185 156 201 192 248 238 201
Short-Term Investments		 831 716 700 615 810 813 888 805 663 593 621
Prepaid Expenses		 22 28 22 31 34 25 22 19 20 15 19
Other Current Assets		 27 33 34 52 35 28 16 15 15 11 3.00
Plant, Property, & Equipment, net		 34 37 45 50 51 49 48 46 44 42 38
Total Noncurrent Assets		 259 202 189 259 178 115 77 79 85 75 115
Long-Term Investments		 143 90 80 151 100 40 2.00 8.00 16 10 54
Other Noncurrent Operating Assets		 116 112 109 108 78 75 75 71 69 65 61
Total Liabilities & Shareholders' Equity		 1,394 1,254 1,220 1,191 1,293 1,186 1,252 1,156 1,075 974 997
Total Liabilities		 695 654 654 671 586 551 687 625 526 538 473
Total Current Liabilities		 177 179 180 200 204 199 215 192 210 235 209
Accounts Payable		 11 28 12 17 16 15 13 22 29 42 39
Current Deferred Revenue		 103 97 103 103 124 113 105 72 71 52 34
Other Current Liabilities		 2.98 54 65 80 64 71 97 98 110 141 136
Total Noncurrent Liabilities		 518 475 474 471 382 352 472 433 316 303 264
Long-Term Debt		 - - - - - - 47 48 97 98 100
Noncurrent Deferred Revenue		 383 330 330 326 242 214 289 219 60 53 45
Other Noncurrent Operating Liabilities		 135 145 144 145 140 138 136 166 159 152 119
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 699 600 566 520 707 635 565 531 549 436 524
Total Preferred & Common Equity		 699 600 566 520 707 635 565 531 549 436 524
Total Common Equity		 699 600 566 520 707 635 565 531 549 436 524
Common Stock		 1,183 1,226 1,267 1,291 1,561 1,582 1,602 1,775 1,793 1,815 2,138
Retained Earnings		 -475 -622 -697 -768 -853 -946 -1,038 -1,244 -1,244 -1,379 -1,613
Accumulated Other Comprehensive Income / (Loss)		 -9.80 -4.00 -4.00 -3.00 -1.00 -1.00 1.00 - - - -1.00

Annual Metrics And Ratios for Arcus Biosciences

This table displays calculated financial ratios and metrics derived from Arcus Biosciences' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 491.15% 79.58% 420.00% 391.03% -70.76% 4.46% 120.51% -4.26%
EBITDA Growth		 0.00% -196.74% 4.05% -71.93% -45.33% 153.33% -503.13% -20.16% -11.29% -18.77%
EBIT Growth		 0.00% -189.66% 5.18% -67.23% -47.29% 144.72% -580.00% -13.26% -10.37% -24.10%
NOPAT Growth		 0.00% -193.92% -2.65% -61.70% -39.78% 159.95% -476.66% -21.43% 2.94% -16.97%
Net Income Growth		 0.00% -195.39% 6.57% -70.81% -45.20% 143.09% -603.77% -14.98% 7.82% -24.74%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11.86% 24.34% -4.78%
Operating Cash Flow Growth		 0.00% -93.60% -71.58% -70.86% 251.10% -330.63% 271.09% -169.86% 44.44% -183.53%
Free Cash Flow Firm Growth		 0.00% 0.00% -134.58% -82.21% 290.96% -381.15% 230.51% -170.63% 44.13% -155.23%
Invested Capital Growth		 0.00% 0.00% -15.40% 5.99% -852.93% 169.16% -398.76% 16.01% -13.61% 39.00%
Revenue Q/Q Growth		 0.00% 0.00% 3.88% 120.20% 0.28% 898.62% -74.11% -2.50% -1.90% 2.92%
EBITDA Q/Q Growth		 0.00% 0.00% 8.23% -5.64% -40.96% 123.51% -374.03% -7.64% -19.79% 8.66%
EBIT Q/Q Growth		 0.00% 0.00% 8.74% -5.86% -40.41% 119.75% -416.02% -4.91% -23.60% 8.00%
NOPAT Q/Q Growth		 0.00% 0.00% -0.26% -4.78% -38.16% 126.66% -371.12% -5.26% -3.77% -2.93%
Net Income Q/Q Growth		 0.00% 0.00% 1.81% -5.35% -40.41% 119.03% -435.69% -4.78% -4.81% -3.52%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.46%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -111.78% -3.33% -26.77% -4.87% -1.81% -6.25% -7.59% -4.33%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -3.50% -23.13% -45.36% 22.28% -8.88% -1.38% -3.38%
Invested Capital Q/Q Growth		 0.00% 0.00% -18.18% -23.66% 3.30% 180.19% 2.48% 6.05% 4.18% 8.79%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% -3,542.39% -574.94% -550.45% -153.85% 16.71% -230.36% -264.96% -133.72% -140.89%
Operating Margin		 0.00% -3,782.09% -656.76% -591.39% -158.97% 14.10% -250.00% -290.60% -127.91% -156.28%
EBIT Margin		 0.00% -3,727.25% -597.83% -556.72% -157.69% 14.36% -235.71% -255.56% -127.91% -139.68%
Profit (Net Income) Margin		 0.00% -3,756.69% -593.73% -564.73% -157.69% 13.84% -238.39% -262.39% -109.69% -142.92%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 96.36% 100.38% 101.99% 100.35% 100.00%
Interest Burden Percent		 98.83% 100.79% 99.31% 101.44% 100.00% 100.00% 100.76% 100.67% 85.45% 102.32%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 3.64% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -34.50% -25.51% -42.48% -36.93% 7.89% -35.62% -54.87% -59.77% -63.26%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -212.26% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -27.65% -21.46% -34.94% -25.22% 4.65% -17.98% -24.51% -29.40% -30.14%
Return on Assets (ROA)		 0.00% -27.87% -21.31% -35.44% -25.22% 4.48% -18.18% -25.16% -25.21% -30.84%
Return on Common Equity (ROCE)		 0.00% 16.22% -10.67% -42.48% -36.93% 7.89% -35.62% -54.87% -59.77% -63.26%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 73.39% -21.11% -51.70% -24.49% 6.29% -40.64% -66.45% -58.35% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -37 -38 -62 -87 52 -196 -238 -231 -270
NOPAT Margin		 0.00% -2,647.47% -459.73% -413.98% -111.28% 13.59% -175.00% -203.42% -89.53% -109.39%
Net Nonoperating Expense Percent (NNEP)		 0.00% -17.77% -5.12% -10.07% -7.84% 0.14% -7.81% -6.89% -5.75% -8.93%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -29.83% -51.52% -43.34% -37.01%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 540.41% 162.41% 168.19% 55.13% 18.80% 92.86% 100.00% 46.51% 44.53%
R&D to Revenue		 0.00% 3,341.68% 594.35% 523.21% 203.85% 67.10% 257.14% 290.60% 173.64% 211.74%
Operating Expenses to Revenue		 0.00% 3,882.09% 756.76% 691.39% 258.97% 85.90% 350.00% 390.60% 227.91% 256.28%
Earnings before Interest and Taxes (EBIT)		 -18 -53 -50 -84 -123 55 -264 -299 -330 -345
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -50 -48 -83 -120 64 -258 -310 -345 -348
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 2.04 2.83 3.36 3.38 2.28 3.09 2.81 4.08
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.04 2.83 3.36 3.38 2.28 3.09 2.81 4.08
Price to Revenue (P/Rev)		 0.00 84.93 57.32 30.88 21.61 7.42 13.37 12.22 5.28 10.42
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 53.64 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 1.86% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 13.43 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 120.18 26.08 18.33 12.18 5.64 3.21 4.82 1.62 6.73
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 33.78 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 39.31 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 41.55 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 8.56 0.00 0.82 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 7.82 0.00 0.81 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.16
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.16
Financial Leverage		 0.00 -1.15 -1.12 -1.13 -1.39 -1.05 -1.21 -1.79 -1.91 -1.66
Leverage Ratio		 0.00 1.24 1.20 1.20 1.46 1.76 1.96 2.18 2.37 2.05
Compound Leverage Factor		 0.00 1.25 1.19 1.22 1.46 1.76 1.97 2.20 2.03 2.10
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.01% 13.56%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.01% 13.56%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 147.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -47.01% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 90.99% 86.44%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.14 -0.28
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.74 2.62
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.14 -0.28
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.21 -0.37
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.09 3.37
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.21 -0.37
Altman Z-Score		 0.00 1.56 7.05 5.38 3.68 3.21 0.96 0.18 -0.05 1.25
Noncontrolling Interest Sharing Ratio		 0.00% 147.01% 58.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 13.90 15.29 8.49 6.05 7.60 5.53 4.52 4.50 4.36
Quick Ratio		 0.00 13.81 15.15 8.30 5.99 3.01 5.23 4.13 4.33 4.25
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -15 -35 -64 122 -342 446 -315 -176 -449
Operating Cash Flow to CapEx		 -315.78% -454.46% -1,148.70% -3,816.21% 3,700.00% -984.62% 7,300.00% -1,275.00% -2,833.33% -24,100.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 223.00 -157.50 -44.00 -56.15
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 219.00 -153.00 -42.50 -60.25
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 216.00 -165.00 -44.00 -60.50
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.04 0.06 0.16 0.32 0.08 0.10 0.23 0.22
Accounts Receivable Turnover		 0.00 56.52 154.69 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.13 0.75 1.47 7.75 17.89 3.34 2.72 5.27 5.68
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 6.46 2.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 6.46 2.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -23 -26 -24 -233 161 -481 -404 -459 -280
Invested Capital Turnover		 0.00 -0.13 -0.34 -0.60 -0.61 -10.67 -0.70 -0.26 -0.60 -0.67
Increase / (Decrease) in Invested Capital		 0.00 -23 -3.47 1.56 -208 394 -642 77 -55 179
Enterprise Value (EV)		 0.00 170 218 275 950 2,162 359 564 419 1,662
Market Capitalization		 120 120 479 463 1,685 2,843 1,497 1,430 1,363 2,573
Book Value per Share		 $0.00 ($39.56) $5.29 $3.57 $7.74 $11.99 $9.07 $6.17 $5.30 $5.84
Tangible Book Value per Share		 $0.00 ($39.56) $5.29 $3.57 $7.74 $11.99 $9.07 $6.17 $5.30 $5.84
Total Capital		 0.00 154 235 164 502 842 657 462 533 730
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 48 99
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 48 99
Net Debt		 0.00 -176 -261 -188 -735 -681 -1,138 -866 -944 -911
Capital Expenditures (CapEx)		 4.10 5.51 3.74 1.93 3.00 26 6.00 24 6.00 2.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -12 -15 -18 -115 597 -135 -112 -188 -205
Debt-free Net Working Capital (DFNWC)		 0.00 164 242 170 614 1,096 874 647 790 776
Net Working Capital (NWC)		 0.00 164 242 170 614 1,096 874 647 790 776
Net Nonoperating Expense (NNE)		 5.24 16 11 23 36 -0.96 71 69 52 83
Net Nonoperating Obligations (NNO)		 0.00 -176 -261 -188 -735 -681 -1,138 -866 -944 -911
Total Depreciation and Amortization (D&A)		 1.31 2.61 1.91 0.94 3.00 9.00 6.00 -11 -15 -3.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -818.12% -173.96% -121.81% -146.79% 155.87% -120.54% -95.73% -72.87% -83.00%
Debt-free Net Working Capital to Revenue		 0.00% 11,616.63% 2,897.32% 1,133.33% 787.37% 286.16% 780.36% 552.99% 306.20% 314.17%
Net Working Capital to Revenue		 0.00% 11,616.63% 2,897.32% 1,133.33% 787.37% 286.16% 780.36% 552.99% 306.20% 314.17%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.14) ($3.29)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 44.53M 45.97M 70.88M 69.35M 72M 74M 90.10M 107.40M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.14) ($3.29)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 44.53M 45.97M 70.88M 73.97M 72M 74M 90.10M 107.40M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 34.62M 43.83M 54.79M 71.06M 73.01M 90.86M 105.84M 125.35M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -37 -38 -62 -87 52 -196 -238 -217 -270
Normalized NOPAT Margin		 0.00% -2,647.47% -459.73% -413.98% -111.28% 13.59% -175.00% -203.42% -84.11% -109.39%
Pre Tax Income Margin		 0.00% -3,756.69% -593.73% -564.73% -157.69% 14.36% -237.50% -257.27% -109.30% -142.92%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -132.00 -149.50 -82.50 -43.13
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -98.00 -119.00 -57.75 -33.78
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -135.00 -161.50 -84.00 -43.38
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -101.00 -131.00 -59.25 -34.03
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Arcus Biosciences

This table displays calculated financial ratios and metrics derived from Arcus Biosciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 125,349,476.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 125,349,476.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -1.02
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -3.03% -8.82% 480.00% 34.48% 50.00% -16.13% -80.69% 310.26% -45.83% 26.92% -39.29%
EBITDA Growth		 -4.76% -32.84% 92.41% -28.95% -43.94% -19.10% -489.47% 101.02% -40.00% 1.89% -12.50%
EBIT Growth		 -4.62% -21.21% 96.10% -25.68% -33.82% -28.75% -593.75% 102.15% -45.05% -0.97% -12.61%
NOPAT Growth		 -14.29% -22.97% 81.40% -27.71% -31.25% -13.19% -662.50% 92.45% -35.24% -10.68% -9.84%
Net Income Growth		 -9.23% -20.90% 95.00% -24.00% -29.58% -16.05% -2,700.00% 100.00% -46.74% -12.77% -14.29%
EPS Growth		 0.00% 0.00% 95.41% 1.92% -6.38% 0.93% -2,180.00% 100.00% -27.00% 17.76% 10.53%
Operating Cash Flow Growth		 22.22% -25.71% 97.96% -64.91% 141.27% -13.64% -6,500.00% -41.49% -473.08% -20.00% -4.55%
Free Cash Flow Firm Growth		 -148.97% -123.84% 58.52% -4.63% 79.45% 87.85% 29.46% 31.62% -1,007.76% -1,413.45% -464.98%
Invested Capital Growth		 12.82% 16.01% 12.61% 15.77% -11.40% -13.61% -9.79% 24.87% 35.91% 39.00% 40.85%
Revenue Q/Q Growth		 10.34% -3.13% 367.74% -73.10% 23.08% -45.83% 7.69% 471.43% -83.75% 26.92% -48.48%
EBITDA Q/Q Growth		 13.16% -34.85% 92.77% -1,533.33% 3.06% -11.58% -5.66% 100.89% -13,400.00% 21.80% -21.15%
EBIT Q/Q Growth		 8.11% -17.65% 96.25% -3,000.00% 2.15% -13.19% -7.77% 101.80% -6,700.00% 21.21% -20.19%
NOPAT Q/Q Growth		 3.61% -13.75% 82.42% -562.50% 0.94% 1.90% -18.45% 93.44% -1,675.00% 19.72% -17.54%
Net Income Q/Q Growth		 5.33% -14.08% 95.06% -2,225.00% 1.08% -2.17% -19.15% 100.00% 0.00% 21.48% -20.75%
EPS Q/Q Growth		 9.62% -14.89% 0.00% -1,940.00% 1.96% -7.00% -6.54% 100.00% 0.00% 30.71% -15.91%
Operating Cash Flow Q/Q Growth		 -10.53% -39.68% 97.73% -4,600.00% 127.66% -484.62% -32.00% -0.76% 27.07% -23.71% -15.00%
Free Cash Flow Firm Q/Q Growth		 13.50% -18.02% 52.24% -114.58% 83.01% 30.20% -177.19% -108.02% -175.25% 4.64% -3.48%
Invested Capital Q/Q Growth		 3.15% 6.05% 3.96% 3.61% -28.07% 4.18% 7.19% 34.04% -9.25% 8.79% 10.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -206.25% -287.10% -4.14% -251.28% -197.92% -407.69% -400.00% 0.63% -511.54% -315.15% -741.18%
Operating Margin		 -250.00% -293.55% -11.03% -271.79% -218.75% -396.15% -435.71% -5.00% -546.15% -345.45% -788.24%
EBIT Margin		 -212.50% -258.06% -2.07% -238.46% -189.58% -396.15% -396.43% 1.25% -507.69% -315.15% -735.29%
Profit (Net Income) Margin		 -221.88% -261.29% -2.76% -238.46% -191.67% -361.54% -400.00% 0.00% -519.23% -321.21% -752.94%
Tax Burden Percent		 102.90% 101.25% 100.00% 100.00% 100.00% 101.08% 100.00% 0.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.47% 100.00% 133.33% 100.00% 101.10% 90.29% 100.90% 0.00% 102.27% 101.92% 102.40%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -48.08% -54.87% -35.35% -41.47% -49.77% -59.77% -63.17% -50.34% -68.13% -63.26% -69.95%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -19.73% -24.75% -0.39% -48.96% -40.82% -91.05% -45.65% 0.29% -109.48% -68.01% -161.20%
Return on Assets (ROA)		 -20.60% -25.06% -0.51% -48.96% -41.27% -83.10% -46.06% 0.00% -111.96% -69.32% -165.07%
Return on Common Equity (ROCE)		 -48.08% -54.87% -35.35% -41.47% -49.77% -59.77% -63.17% -50.34% -68.13% -63.26% -69.95%
Return on Equity Simple (ROE_SIMPLE)		 -56.35% 0.00% -32.67% -39.21% -47.79% 0.00% -73.63% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -56 -64 -11 -74 -74 -72 -85 -5.60 -99 -80 -94
NOPAT Margin		 -175.00% -205.48% -7.72% -190.26% -153.13% -277.31% -305.00% -3.50% -382.31% -241.82% -551.76%
Net Nonoperating Expense Percent (NNEP)		 -1.40% -1.73% 0.67% -1.86% -1.86% -2.42% -2.59% 0.61% -3.98% -2.82% -3.95%
Return On Investment Capital (ROIC_SIMPLE)		 - -13.79% - - - -13.53% -14.75% -0.87% -18.61% -10.93% -15.03%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 93.75% 93.55% 22.07% 76.92% 62.50% 107.69% 100.00% 18.13% 103.85% 78.79% 170.59%
R&D to Revenue		 256.25% 300.00% 75.17% 294.87% 256.25% 388.46% 435.71% 86.88% 542.31% 366.67% 717.65%
Operating Expenses to Revenue		 350.00% 393.55% 111.03% 371.79% 318.75% 496.15% 535.71% 105.00% 646.15% 445.45% 888.24%
Earnings before Interest and Taxes (EBIT)		 -68 -80 -3.00 -93 -91 -103 -111 2.00 -132 -104 -125
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -66 -89 -6.00 -98 -95 -106 -112 1.00 -133 -104 -126
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.57 3.09 2.00 2.18 2.47 2.81 1.56 1.57 3.32 4.08 5.17
Price to Tangible Book Value (P/TBV)		 2.57 3.09 2.00 2.18 2.47 2.81 1.56 1.57 3.32 4.08 5.17
Price to Revenue (P/Rev)		 11.14 12.22 5.96 5.61 5.32 5.28 5.89 3.29 6.03 10.42 11.47
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 3.23 4.82 1.34 1.52 1.35 1.62 0.00 0.12 2.94 6.73 8.18
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.08 0.10 0.09 0.18 0.22 0.16 0.19
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.08 0.10 0.09 0.18 0.22 0.16 0.19
Financial Leverage		 -1.76 -1.79 -1.64 -1.68 -1.84 -1.91 -1.66 -1.55 -1.79 -1.66 -1.64
Leverage Ratio		 2.12 2.18 1.95 2.00 2.25 2.37 1.98 1.91 2.22 2.05 2.04
Compound Leverage Factor		 2.15 2.18 2.60 2.00 2.28 2.14 2.00 0.00 2.27 2.09 2.09
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 7.68% 9.01% 8.29% 15.02% 18.35% 13.56% 16.03%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 7.68% 9.01% 8.29% 15.02% 18.35% 13.56% 16.03%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 92.32% 90.99% 91.71% 84.98% 81.65% 86.44% 83.97%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.16 -0.14 -0.11 -0.28 -0.26 -0.28 -0.28
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 3.63 2.74 2.13 2.39 1.95 2.62 2.14
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.16 -0.14 -0.11 -0.28 -0.26 -0.28 -0.28
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.21 -0.21 -0.16 -0.41 -0.37 -0.37 -0.36
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 4.69 4.09 3.14 3.51 2.83 3.37 2.79
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.21 -0.21 -0.16 -0.41 -0.37 -0.37 -0.36
Altman Z-Score		 0.89 0.84 1.50 1.17 0.90 0.60 -0.03 0.43 0.20 1.95 1.76
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.41 4.52 5.22 5.14 5.24 4.50 5.37 4.50 3.65 4.36 4.04
Quick Ratio		 4.00 4.13 4.88 4.87 5.07 4.33 5.19 4.34 3.54 4.25 3.93
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -119 -141 -67 -144 -25 -17 -47 -99 -271 -259 -268
Operating Cash Flow to CapEx		 -630.00% -1,466.67% -50.00% 0.00% 2,600.00% -10,000.00% -13,200.00% 0.00% 0.00% -12,000.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -119.22 0.00 -67.20 0.00 -24.50 -8.55 -47.40 -49.30 -90.47 -129.40 -89.27
Operating Cash Flow to Interest Expense		 -63.00 0.00 -2.00 0.00 26.00 -50.00 -132.00 -66.50 -32.33 -60.00 -46.00
Operating Cash Flow Less CapEx to Interest Expense		 -73.00 0.00 -6.00 0.00 25.00 -50.50 -133.00 -66.50 -32.33 -60.50 -46.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.09 0.10 0.19 0.21 0.22 0.23 0.12 0.23 0.22 0.22 0.22
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 2.86 2.72 5.39 5.26 5.37 5.27 2.91 5.63 5.33 5.68 5.62
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -430 -404 -388 -374 -479 -459 -426 -281 -307 -280 -252
Invested Capital Turnover		 -0.26 -0.26 -0.57 -0.60 -0.58 -0.60 -0.35 -0.80 -0.61 -0.67 -0.70
Increase / (Decrease) in Invested Capital		 63 77 56 70 -49 -55 -38 93 172 179 174
Enterprise Value (EV)		 387 564 318 376 354 419 -126 32 704 1,662 1,932
Market Capitalization		 1,337 1,430 1,413 1,385 1,398 1,363 831 862 1,447 2,573 2,708
Book Value per Share		 $6.98 $6.17 $8.20 $6.98 $6.18 $5.30 $5.02 $5.18 $4.10 $5.84 $4.18
Tangible Book Value per Share		 $6.98 $6.17 $8.20 $6.98 $6.18 $5.30 $5.02 $5.18 $4.10 $5.84 $4.18
Total Capital		 520 462 707 635 612 533 579 646 534 730 624
Total Debt		 0.00 0.00 0.00 0.00 47 48 48 97 98 99 100
Total Long-Term Debt		 0.00 0.00 0.00 0.00 47 48 48 97 98 99 100
Net Debt		 -950 -866 -1,095 -1,009 -1,044 -944 -957 -830 -743 -911 -776
Capital Expenditures (CapEx)		 10 6.00 4.00 0.00 1.00 1.00 1.00 0.00 0.00 1.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -117 -112 -135 -146 -177 -188 -158 -175 -209 -205 -187
Debt-free Net Working Capital (DFNWC)		 682 647 860 823 912 790 839 736 622 776 635
Net Working Capital (NWC)		 682 647 860 823 912 790 839 736 622 776 635
Net Nonoperating Expense (NNE)		 15 17 -7.20 19 19 22 27 -5.60 36 26 34
Net Nonoperating Obligations (NNO)		 -950 -866 -1,095 -1,009 -1,044 -944 -957 -830 -743 -911 -776
Total Depreciation and Amortization (D&A)		 2.00 -9.00 -3.00 -5.00 -4.00 -3.00 -1.00 -1.00 -1.00 0.00 -1.00
Debt-free, Cash-free Net Working Capital to Revenue		 -97.50% -95.73% -56.96% -59.11% -67.30% -72.87% -112.06% -66.79% -87.08% -83.00% -79.24%
Debt-free Net Working Capital to Revenue		 568.33% 552.99% 362.87% 333.20% 346.77% 306.20% 595.04% 280.92% 259.17% 314.17% 269.07%
Net Working Capital to Revenue		 568.33% 552.99% 362.87% 333.20% 346.77% 306.20% 595.04% 280.92% 259.17% 314.17% 269.07%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.08) ($0.05) ($1.02) ($1.00) ($1.07) ($1.14) $0.00 ($1.27) ($0.88) ($1.02)
Adjusted Weighted Average Basic Shares Outstanding		 74.60M 74M 86.20M 91.10M 91.40M 90.10M 98.40M 106.10M 106.50M 107.40M 125.40M
Adjusted Diluted Earnings per Share		 $0.00 ($1.08) ($0.05) ($1.02) ($1.00) ($1.07) ($1.14) $0.00 ($1.27) ($0.88) ($1.02)
Adjusted Weighted Average Diluted Shares Outstanding		 74.60M 74M 86.20M 91.10M 91.40M 90.10M 98.40M 106.50M 106.50M 107.40M 125.40M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 74.86M 90.86M 90.95M 91.43M 91.51M 105.84M 105.89M 106.43M 107.97M 125.35M 125.77M
Normalized Net Operating Profit after Tax (NOPAT)		 -56 -64 2.80 -74 -74 -72 -85 -5.60 -99 -80 -94
Normalized NOPAT Margin		 -175.00% -205.48% 1.93% -190.26% -153.13% -277.31% -305.00% -3.50% -382.31% -241.82% -551.76%
Pre Tax Income Margin		 -215.63% -258.06% -2.76% -238.46% -191.67% -357.69% -400.00% 0.00% -519.23% -321.21% -752.94%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -68.00 0.00 -3.00 0.00 -91.00 -51.50 -111.00 1.00 -44.00 -52.00 -41.67
NOPAT to Interest Expense		 -56.00 0.00 -11.20 0.00 -73.50 -36.05 -85.40 -2.80 -33.13 -39.90 -31.27
EBIT Less CapEx to Interest Expense		 -78.00 0.00 -7.00 0.00 -92.00 -52.00 -112.00 1.00 -44.00 -52.50 -41.67
NOPAT Less CapEx to Interest Expense		 -66.00 0.00 -15.20 0.00 -74.50 -36.55 -86.40 -2.80 -33.13 -40.40 -31.27
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Arcus Biosciences (RCUS) continues to post modest quarterly revenue while funding its pipeline through heavy R&D spend and periodic equity financing. The last four years show persistent net losses driven largely by R&D, with liquidity supported by equity issuances and a sizable cash/ investment balance. Here are the most noteworthy trends from the four-year view, with the positives listed first, followed by neutral items and then the negatives.

  • Q4 2025: Issuance of Common Equity contributed about $286 million in financing cash inflow, boosting liquidity headroom.
  • Q3 2025: Net cash from investing activities of about $79 million, driven by sale/maturity of investments, provided a meaningful cash inflow during the quarter.
  • Across several 2025 quarters, financing activities generated material cash inflows from equity issuances, helping to fund ongoing operations.
  • As of Q3 2025, Arcus held roughly $238 million in cash and $593 million in short-term investments, totaling about $831 million in readily available liquidity.
  • Operating revenue in 2025 hovered in the mid-teens to low-40s million range annually in the provided sample quarters, indicating a relatively flat top-line vs. peers with rising R&D spend.
  • R&D expense remained the dominant cost, running around $120–$141 million per quarter in 2025, underscoring a broad pipeline investment profile.
  • Long-term debt remained modest (around $98 million) with total liabilities near half a billion dollars, suggesting manageable leverage for a biotechnology company at this stage.
  • Net income was negative in every 2025 quarter (e.g., approximately -$106M in Q4 2025, -$93M in Q2 2025, -$135M in Q3 2025, -$112M in Q1 2025), reflecting ongoing losses driven by high R&D spend.
  • Cash flow from operating activities was negative across all 2025 quarters (roughly -$120M in Q4 2025, -$97M in Q3 2025, -$133M in Q2 2025, -$132M in Q1 2025), indicating a continued cash burn at the operating level.
  • Impairment charges and elevated one-time costs occurred (e.g., a $20 million impairment in Q1 2025), adding to the quarterly losses beyond ongoing operating expenses.
05/14/26 06:29 PM ETAI Generated. May Contain Errors.

Arcus Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Arcus Biosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Arcus Biosciences' net income appears to be on an upward trend, with a most recent value of -$353 million in 2025, rising from -$17.97 million in 2016. The previous period was -$283 million in 2024. View Arcus Biosciences' forecast to see where analysts expect Arcus Biosciences to go next.

Arcus Biosciences' total operating income in 2025 was -$386 million, based on the following breakdown:
  • Total Gross Profit: $247 million
  • Total Operating Expenses: $633 million

Over the last 9 years, Arcus Biosciences' total revenue changed from $0.00 in 2016 to $247 million in 2025, a change of 24,700,000,000.0%.

Arcus Biosciences' total liabilities were at $508 million at the end of 2025, a 23.6% decrease from 2024, and a 1,287.3% increase since 2017.

In the past 8 years, Arcus Biosciences' cash and equivalents has ranged from $57.94 million in 2019 to $222 million in 2025, and is currently $222 million as of their latest financial filing in 2025.

Over the last 9 years, Arcus Biosciences' book value per share changed from 0.00 in 2016 to 5.84 in 2025, a change of 584.4%.


Related Companies

Financial statements for NYSE:RCUS last updated on 5/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
What Expenses Can Be Deducted From Capital Gains Tax This Year?
Capital gains taxes can quietly erode investment returns - but the tax code offers legitimate ways to potentia...
SmartAsset | Sponsoredtc pixel
Musk's acquisition pattern points to ONE stock
Musk needed solar - he acquired SolarCity. Needed data - he bought Twitter. The pattern is clear: when a suppl...
Behind the Markets | Sponsoredtc pixel
Trump Just Named His Secret AI Project. It's Called "Golden Dawn."
Behind a hidden government lab in Tennessee, 40,000 scientists are reportedly finishing work on an AI system d...
InvestorPlace | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel